RSS Content

AtriCure to Present at the Leerink Swann 2014 Global Healthcare Conference

WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 20, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Leerink Swann 2014 Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Wednesday, February 12, 2014. Management is scheduled to present at 11:30 a.m. Eastern Time.

A live audio webcast and replay of the presentation will be available for 30 days following the presentation at www.atricure.com.

About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide. The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide.

Source: AtriCure, Inc.

AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
awade@atricure.com
or
Investor Relations Contact
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com